Current Trials
Familial Chylomicronemia Syndrome
The APPROACH Extension Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx)
ISIS 304801-CS7, The APPROACH Open Label Extension Study Volanesorsen (ISIS 304801) An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS).
Fatty Liver Diseases – NAFLD and NASH
NN9931-4296
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily versus Placebo in Subjects with Non-alcoholic Steatohepatitis
EMMINENCE™
A Study to Evaluate the Safety, Tolerability, and Efficacy of MSDC 0602K in Patients with NASH
Clinical Trial in Adults at High-Risk for Fatty Liver Disease
A cross-sectional study evaluating the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in high-risk undiagnosed adults in South Florida.
NASH
Phase 2 Study of MGL-3196 in Patients with Non-Alcoholic Steatohepatitis (NASH).
Heart Failure
EMPagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
A phase III randomized, double-blind placebo controlled trial to evaluate efficacy and safety of once daily empagliflozin 10 mg in patients with heart failure with preserved ejection fraction.
EMPagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
A phase III randomized, double-blind study to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF < 40%).
Heterozygous Familial Hypercholesterolemia
R1500-CL-1643
Study of Evinacumab (REGN1500) in Participants with Persistent Hypercholesterolemia
ORION-9
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia (HeFH)
Homozygous Familial Hypercholesterolemia
R727-CL-1629
Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
R727-CL-1628
Study in Participants ≥12 years of age with Homozygous Familial Hypercholesterolemia (HoFH)
A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
AAV8-mediated low density lipoprotein receptor (LDLR) gene replacement in subjects with homozygous familial hypercholesterolemia (HoFH).
Hypercholesterolemia
A Study in Subjects with Type 2 Diabetes Mellitus with Hypercholesterolemia/Mixed Dyslipidemia
A double-blind, randomized, placebo-controlled, multicenter study to evaluate safety, tolerability, and efficacy of evolocumab (AMG 145) on LDL-C in subjects with Type 2 Diabetes Mellitus and hypercholesterolemia/mixed dyslipidemia on maximally tolerated statin therapy.
CASCADE-FH Registry
Cascade Screening for Awareness and Detection of familial hypercholesterolemia.
LOWER Registry
LOWER: Lomitapide observational worldwide evaluation registry. This registry is a multicentre, long-term, prospective, observational cohort study designed to evaluate the long term safety and effectiveness of lomitapide.
ROYAL-1
A 12-week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins (ROYAL-1).
Dyslipidemia
GOULD Registry
Getting to an improved understanding of LDL-C and dyslipidemia management (GOULD): a registry of high cardiovascular risk patients in the United States.
ODYSSEY DM-Dyslipidemia Study
A randomized, open-label, parallel group study to evaluate the efficacy and safety of alirocumab versus usual care in patients with Type 2 Diabetes and mixed dyslipidemia at high cardiovascular risk with non-HDL- C not adequately controlled with maximally tolerated statin therapy.
Hyperlipidemia
ORION-10
Inclisiran for Participants with Atherosclerotic Cardiovascular Disease and Elevated Low-Density Lipoprotein Cholesterol
1002FDC-053
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in patients with Treated with Maximally Tolerated Statin Therapy
1002-047 CLEAR Wisdom
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk
1002-038
Triple Therapy in Patients with Elevated LDL-C
1002-050
Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg
1002-040 CLEAR Harmony
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients with Hyperlipidemia and High CV Risk
Hyperlipoproteinemia(a)
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients with Hyperlipoproteinemia(a) and Cardiovascular Disease
A randomized, double-blind, placebo-controlled, dose-ranging phase 2 study of ISIS 681257 administered subcutaneously to patients with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Hypertriglyceridemia
ISIS 678354-CS2
Study of ISIS 678354 (AKCEA-APOCIII-LR) in Patients with Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
INDIGO-1
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
STRENGTH
Outcomes Study to Assess Statin Residual risk reduction with EpaNova in high CV risk patients with Hypertriglyceridemia
Statin Intolerance
CLEAR Tranquility
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C.
CLEAR Outcomes
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant.
Type 2 Diabetes
CIRT
Cardiovascular Inflammation Reduction Trial
BEST
Bexagliflozin Efficacy and Safety Trial
Menu
Newsletter
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.